- Scorpius Holdings Inc. to launch first cGMP mammalian manufacturing campaign in Q3 2024.
- New facility in San Antonio to support early-stage clinical programs and expand CDMO operations.
Scorpius Holdings Inc., an integrated contract development and manufacturing organization (CDMO), has announced the expected launch of its first cGMP mammalian manufacturing campaign at its San Antonio facility in the third quarter of 2024.
Jeff Wolf, CEO of Scorpius, expressed pride in the team’s rapid progress, stating, “Our manufacturing and quality teams have worked exceptionally hard to get our mammalian facilities operational in less than two years, well ahead of the typical timing for such complex buildouts. Scorpius is now extremely well-positioned to support a wide range of early-stage clinical programs.”
The San Antonio facility features cleanrooms with mobile equipment, allowing for customized configurations to meet specific project needs. This strategic design aims to expand Scorpius’s scope of services as clients advance their clinical programs. The company has already secured bookings for additional cGMP activities in the mammalian building for 2025, indicating strong demand and confidence in their expanded capabilities.
